New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareARA-290 vs Follistatin

ARA-290 vs Follistatin

Side-by-side comparison of key properties, dosing, and research.

Immune SupportRecovery & Repair
ARA-290
Anabolic & IGF
Follistatin
Summary
ARA-290 is a synthetic 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, it selectively activates the innate repair receptor (IRR) without stimulating hematopoiesis, providing tissue protection, anti-inflammation, and neuropathy relief.
Follistatin is an endogenous glycoprotein that acts as a potent inhibitor of myostatin and activin, two proteins that limit muscle growth. By binding and neutralizing myostatin, follistatin removes the primary brake on skeletal muscle hypertrophy, enabling significant muscle growth beyond normal physiological limits. It is distinct from its isoforms Follistatin 315 and Follistatin 344 in tissue distribution and binding affinity.
Half-Life
~2–4 hours (SC administration)
~3–5 hours (endogenous form)
Admin Route
SubQ
IM, SubQ
Research
Typical Dose
4 mg (fixed dose)
50–100 mcg per injection site
Frequency
Once daily
Every other day or 2–3x per week
Key Benefits
  • Reduces neuropathic pain from small fiber neuropathy
  • Anti-inflammatory without immune suppression
  • Tissue protection after ischemia/reperfusion injury
  • Promotes nerve fiber regeneration
  • Improves symptoms of sarcoidosis-associated neuropathy
  • May reduce insulin resistance and improve metabolic health
  • Shown to improve autonomic neuropathy symptoms
  • Potent myostatin inhibition enabling supraphysiological muscle growth
  • Increases skeletal muscle mass and fiber size
  • May accelerate recovery from muscle injury
  • Potential benefits in muscular dystrophy and sarcopenia
  • Synergistic with IGF-1 and growth hormone in anabolic protocols
  • Animal studies show dramatic increases in muscle mass
  • Reduces muscle fibrosis in dystrophic models
Side Effects
  • Injection site reactions
  • Mild fatigue at initiation
  • Transient warm sensation post-injection
  • Rare: mild headache
  • Potential for excessive muscle growth if doses are not controlled
  • FSH suppression with implications for fertility in women
  • Theoretical risk of cardiac hypertrophy with prolonged high-dose use
  • Limited human safety data available
  • +1 more
Stacks With